Soiken Holdings Inc. (2385.T)
Tokyo · JPY · Healthcare · Biotechnology
¥218 (+0.46%) as of
Key statistics
- Market cap
- 5.70B
- P/E (TTM)
- 26.88
- Forward P/E
- 5.38
- EPS (TTM)
- 8.11
- Dividend yield
- 4.61%
- 52-week range
- 180.00 – 325.00
- Beta
- 0.13
- Revenue (TTM)
- 3.87B
- Profit margin
- 5.48%
- Volume
- 64.10k
About Soiken Holdings Inc.
Soiken Holdings Inc. engages in the development of biomarkers in Japan and internationally. The company is involved in the development and sale of cosmetics and dietary supplements comprising imidapeptides; licensing and development of biomarker technology; provision of marketing research and post-marketing surveys for dietary supplements; and research, development, and sale of functional materials, such as lactoferrin, as well as pharmaceutical products from ascochlorin derivatives. It also provides clinical evaluation tests for foodstuffs using biomarker technology; support for pharmaceutical clinical research and epidemiology studies; and services to health insurance societies, including contracted health guidance, specific health checkup promotion services for the dependents of insured, and service to prevent diabetes. Soiken Holdings Inc. was incorporated in 1994 and is headquartered in Toyonaka, Japan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Toyonaka, Japan
- Employees
- 45
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.